<DOC>
	<DOCNO>NCT01585688</DOCNO>
	<brief_summary>The primary objective evaluate safety tolerability hLL1-DOX , determine maximum tolerate dose ( MTD ) regimen ( term dose associate dose schedule ) . The secondary objective obtain information efficacy , pharmacodynamics , pharmacokinetics , immunogenicity , determine optimal dose subsequent study .</brief_summary>
	<brief_title>Phase I/II Study hLL1-DOX Relapsed NHL CLL</brief_title>
	<detailed_description>Patients receive hLL1-DOX one 4 dose level administer Days 1 , 4 , 8 11 21-day treatment cycle continue absence progression unacceptable toxicity total 8 cycle . After treatment , follow-up do 4 , 8 12 week post-treatment continue do every 3 month 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Male female , age ≥ 18 year Able provide sign , informed consent Histologically confirm diagnosis recurrent Bcell nonHodgkin 's lymphoma ( histology WHO criteria ) recurrent chronic lymphocytic leukemia ( NCI criterion ) ( Reference Appendix C ) Received least one prior treatment standard therapy ( previous antibody therapy acceptable ) Measurable disease least one lesion ≥ 1.5 cm NHL ALC &gt; 5,000 CLL Adequate performance status ( ≥ 70 Karnofsky scale ) estimate life expectancy least 6 month Documented negative hepatitis B screen , per NCCN guideline ( hepatitis B surface antigen/antibodies , core antigen/antibodies , hepatitis B eantigen ) At least 12 week beyond stem cell transplant 4 week beyond chemotherapy immunotherapy , major surgery , experimental treatment , radiation therapy index lesion , acute toxicity prior therapy resolve less Grade 2 toxicity NCI CTC version 4.0 Laboratory parameter : Adequate hematology without ongoing transfusional support Hemoglobin &gt; /= 10 g/dL Absolute neutrophil count &gt; /= 1.5 x 10 9/L Platelets &gt; /= 75 x 10 9/L Creatinine bilirubin &lt; /= 1.5 x IULN AST ALT &lt; /= 2.5 x IULN Adequate cardiac function ( MUGA scan 2D ECHO LVEF ≥ 55 % , EKG medically relevant arrhythmia uncontrolled medication ) Pregnant lactate woman . Women childbearing potential must negative pregnancy test . Pregnancy test require postmenopausal surgically sterilize woman . Women childbearing potential fertile men practice unwilling practice birth control enrol study least 12 week last milatuzumab infusion Prior therapy human humanize monoclonal antibody , unless HAHA test negative Prior treatment trastuzumab Bulky disease CT , define single mass &gt; 10 cm great diameter Known HIV positive active hepatitis B C , presence hepatitis B surface antigens presence hepatitis C antibody New York Heart Classification III IV heart disease ( see Appendix G ) . Other severe cardiovascular cardiopulmonary disease , include COPD Baseline BNP &gt; 2 x IULN Patients uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality exclude Patients recent ( ≤ 6 month ) cardiac angina , difficult control congestive heart failure , uncontrolled hypertension , difficult control cardiac arrhythmia exclude Known autoimmune disease presence autoimmune phenomenon At least 7 day beyond infection require intravenous antibiotic use ( Oral antibiotic may administer prophylactically clinically indicate ) Systemic corticosteroid within 2 week , except low dose regimen ( prednisone , ≤ 20 mg/day , equivalent ) may continue unchanged Substance abuse concurrent medical psychiatric condition , Investigator 's opinion , could confound study interpretation affect patient 's ability tolerate complete study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>NHL</keyword>
	<keyword>CLL</keyword>
</DOC>